Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down – Here’s What Happened

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) gapped down before the market opened on Friday . The stock had previously closed at $10.27, but opened at $9.66. Telix Pharmaceuticals shares last traded at $9.4810, with a volume of 60,777 shares trading hands.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Citigroup boosted their price target on shares of Telix Pharmaceuticals from $22.00 to $22.50 and gave the company a “buy” rating in a report on Tuesday, February 24th. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a report on Monday, April 13th. Wedbush reiterated an “outperform” rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a research note on Monday, April 13th. Wall Street Zen upgraded shares of Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, April 11th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $21.13.

Telix Pharmaceuticals Stock Down 7.3%

The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. The business’s 50 day moving average price is $9.83 and its 200-day moving average price is $8.74.

Telix Pharmaceuticals (NASDAQ:TLX) last announced its quarterly earnings data on Friday, February 20th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.06). The firm had revenue of $206.72 million for the quarter, compared to the consensus estimate of $421.50 million. As a group, equities research analysts forecast that Telix Pharmaceuticals Limited will post 0.09 earnings per share for the current year.

Insider Activity

In other Telix Pharmaceuticals news, CEO Christian Behrenbruch acquired 34,500 shares of the company’s stock in a transaction dated Tuesday, April 28th. The stock was bought at an average price of $14.48 per share, for a total transaction of $499,560.00. Following the purchase, the chief executive officer owned 20,709,500 shares in the company, valued at $299,873,560. This represents a 0.17% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link.

Institutional Investors Weigh In On Telix Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers increased its position in Telix Pharmaceuticals by 117.3% in the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after acquiring an additional 1,392 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Telix Pharmaceuticals in the 4th quarter valued at about $89,000. Bank of America Corp DE boosted its stake in shares of Telix Pharmaceuticals by 523.8% in the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after purchasing an additional 8,423 shares during the last quarter. OLD Mission Capital LLC bought a new position in shares of Telix Pharmaceuticals in the 4th quarter valued at about $111,000. Finally, XY Capital Ltd bought a new position in shares of Telix Pharmaceuticals in the 1st quarter valued at about $120,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.